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Patients’ Self-Assessed Functional Status in Heart Failure
by New York Heart Association Class: A Prognostic Predictor
of Hospitalizations, Quality of Life and Death
RICHARD HOLLAND, BA, BM, BCh, DPH, PhD, FFPH,1 BOIKA RECHEL, MD, MSc, MPH, PhD,1
KAROLINA STEPIEN, MD, PhD, MSc,2 IAN HARVEY, BA, MB, BCh, PhD, FFPH,1 AND IAIN BROOKSBY, FRCP3
Norwich, United Kingdom; Nottingham, United Kingdom
ABSTRACT
Background: Clinician-assigned New York Heart Association (NYHA) class is an established predictor
of outcomes in heart failure. This study aims to test whether patients’ self-assessment of functional status
by NYHA class predicts hospital admissions, quality of life, and mortality.
Methods and Results: This was an observational study within a randomized controlled trial. A total of
293 adult patients diagnosed with heart failure were recruited after an emergency admission at 3 acute
hospitals in Norfolk, UK. Outcome measures included number of emergency admissions over 6 months,
self-assessed quality of life measured with the Minnesota Living with Heart Failure questionnaire
(MLHFQ) and EQ-5D at 6 months, and deaths up to 20 months’ follow-up. Patients were grouped into
3 NYHA groups (I/II, III, and IV) based on patients’ self-assigned NYHA class (SA-NYHA). A Poisson
model indicated an increased readmission rate associated with higher SA-NYHA class (adjusted rate ratio
1.21; 95% CI 1.04e1.41; P5 .02). Higher SA-NYHA class at baseline predicted worse quality of life at 6
months’ follow-up (P5 .002 for MLHFQ; P5 .047 for EQ-5D), and was associated with higher mortality
rate (adjusted hazard ratio 1.84; 95% CI 1.10e3.06; P5 .02).
Conclusions: SA-NYHA class is predictive of hospitalization, quality of life, and mortality among
patients with heart failure. (J Cardiac Fail 2010;16:150e156)
Key Words: Heart failure, self-assessment, functional status, survival.
The New York Heart Association (NYHA) classification
is the most commonly used system to describe the impact
of heart failure on a patient’s daily activities.1 The classifi-
cation was originally developed in 1928 and subsequently
revised.2 It classifies patients with heart failure into 4 cate-
gories (I, II, III, IV), with higher class indicating more
severe symptoms, limitation in physical activity, and worse
health. Clinicians assign NYHA class on the basis of their
indirect interpretation of reported patients’ symptoms, med-
ical history, and results from clinical tests on cardiac struc-
ture and function.3 Physician-assigned NYHA class has
been shown to be predictive of outcomes in heart failure
including hospitalization and mortality.4,5 However, be-
cause the NYHA classification involves doctors’ subjective
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judgment of symptoms and clinical data, wide interobserver
variability has been reported.6 Furthermore, disparities be-
tween clinician-assigned NYHA class and patient-reported
limitation in function have been observed in a number of
studies.7
The prognostic value of patients’ own reports of their
symptoms has received less attention in heart failure.8
One approach has been to derive NYHA class through re-
sponses to other brief patient-completed questionnaires.
An early example is the Specific Activity Scale,6 a 5-item
questionnaire assessing maximum physical activity. This
scale has been shown to predict mortality. Nevertheless,
a recent study demonstrated that patient assessed Specific
Activity Scale levels did not appear to correlate with clini-
cian assigned NYHA class.6 Similarly, a study deriving
NYHA class from patient responses to the Kansas City
Cardiomyopathy Questionnaire9 found only ‘‘slight agree-
ment’’ with clinician-assigned NYHA class.10
Our recently completed trial11 asked patients to assign
themselves an NYHA class using standard NYHA class
descriptors, as opposed to other similar questions (eg, Spe-
cific Activity Scale, Kansas City Cardiomyopathy Ques-
tionnaire). This study sets out to examine whether
patient-assigned NYHA class can predict patient outcomes
in terms of mortality, hospital admission, and quality of life.
Methods
Study Design and Participants
This report is based on an observational (cohort) analysis within
a randomized controlled trial. The methods of the HeartMed ran-
domized controlled trial have been described in detail elsewhere.11
Briefly, a total of 293 adult patients, ages 42 to 95 years (mean 77
years, standard deviation 9.3), in whom heart failure was an
important ongoing clinical condition, were recruited from 3 large
district general hospitals in Norfolk after an emergency admission,
and followed over 6 months. The intervention tested was 2 home
visits by community pharmacists who reviewed medication and
gave symptom self-management and lifestyle advice. The inter-
vention did not lead to significant differences in the outcome mea-
sures (hospital admissions, survival, and quality of life) between
the intervention and the control group. The objective of this addi-
tional observational analysis was to test whether the patients’
self-assigned NYHA class (SA-NYHA) at baseline predicted
outcomes.
Baseline Measures
Baseline measures included demographic and socioeconomic
characteristics, medicines at recruitment, abbreviated mental
test,12 clinical information (such as blood pressure), quality of
life measures (EQ-5D13 and Minnesota Living with Heart Failure
Questionnaire [MLHFQ ]14), and self-assigned NYHA classifica-
tion (SA-NYHA). Wherever possible, patients were encouraged
to classify themselves into 1 of the 4 SA-NYHA classes. However,
where patients considered themselves unable (generally because
of their poor health state or cognitive function) to classify them-
selves into an SA-NYHA class, this was recorded, and the
researcher or the carer/relative then helped the patient complete
this. The questionnaire used by patients is presented in Box 1
with SA-NYHA Class I at the top and Class IV at the bottom.15
Outcome Measures
The outcome measures included number of emergency admis-
sions to hospital over 6 months from randomization, quality of
life (measured by a generic instrument [EQ-5D] and a disease-
specific instrument [MLHFQ ]14), and mortality. Data on emer-
gency admissions were obtained from Hospital Episode Statistics.
The EQ-5D consists of 5 questions covering the domains mobility,
self-care, usual activities, pain/discomfort, and anxiety/depres-
sion.13 The EQ-5D is scored from 0.594 to þ1, where þ1 rep-
resents perfect health, 0 represents a state equivalent to death,
and 0.594 the worst imaginable health state.13 The MLHFQ con-
sists of 21 questions each scored from 0 to 5, and total scores vary
from 0 to 105.14 For MLHFQ, higher scores imply worse quality
of life, and a change of 5 points is considered to be clinically sig-
nificant.16 In addition, the MLHFQ can provide a physical dimen-
sion score (calculated from 8 of the questions) and an emotional
dimension score (calculated from 5 of the questions). To maximize
response, the quality of life questionnaires were mailed up to 3
times to participants at both the 3- and the 6-month follow-up.
Mortality data were collected from the Office for National Statis-
tics from the study start up to September 30, 2005. This provided
a minimum of 6 months of data for the last recruited subject, and
up to 20 months of follow-up for those recruited at the start of the
study.
Analysis
We examined differences among SA-NYHA groups. Few
patients classified themselves as Class I (no limitation), and there-
fore this class was merged with Class II (mild limitation). Where
there appeared to be no significant difference among the 3 groups,
we merged Class III (moderate limitation) with Class IV (severe
limitation) and tested the difference between SA-NYHA groups
(I/II) and (III/IV). We used Poisson regression to compare the
number of readmissions between the SA-NYHA groups (Poisson
regression is a standard approach used for analyzing count data).
We compared quality of life scores (EQ-5D and MLHFQ) at 6
months between SA-NYHA groups by using analysis of covari-
ance adjusting for differences in baseline characteristics, and qual-
ity of life scores at baseline and 3 months. As an additional
analysis, we investigated the association between SA-NYHA
groups and both physical and emotional dimension scores of the
MLHFQ. It should be noted that when analyzing EQ-5D scores,
Box 1. Self-completed Questionnaire on SA-NYHA Class
of Heart Failure
Please tick one box containing the description which best summarizes your
ability to do physical activity before coming into hospital:
, I can perform all physical activity without getting short of breath
or tired, or having palpitations.
, I get short of breath or tired, or have palpitations when performing
more strenuous activities. For example, walking on steep inclines
or walking up several flights of steps.
, I get short of breath or tired, or have palpitations when performing
day to day activities. For example, walking on the flat.
, I feel breathless at rest, and am mostly housebound. I am unable to
carry out any physical activity without getting short of breath or
tired, or having palpitations.
SA-NYHA, self-assigned New York Heart Association.
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those who die are allocated a score of 0, which represents a state
equivalent to death.13
Mortality data were analyzed using survival analysis comparing
the SA-NYHA groups with the Cox proportional hazard ratio. The
proportional hazards assumption was checked by inspection of
‘‘log-log’’ plots, Schoenfeld residual plots, and a chi-squared
test using the Schoenfeld residuals.
For each analysis we first conducted an unadjusted analysis of
the effect of SA-NYHA class on a given outcome (eg, admission).
Then, for all multivariable analyses, we entered all the variables
found to be significantly different between the SA-NYHA classes
at baseline. Final models were obtained by stepwise removal of
nonstatistically significant (PO .05) variables from the multivari-
able model, having started with all variables found to be at least of
borderline statistical significance (P! .1) in our univariable anal-
ysis. The importance of trial group (ie, intervention or control) as
a potential confounder of the effect of SA-NYHA class on each
outcome was tested in all final models but was never found to
be statistically significant. Stata version 9.0 was used.
Results
Baseline Characteristics
A total of 293 patients completed the SA-NYHA class
questionnaire at baseline, and approximately equal numbers
of patients fell into the 3 categories (I/II, III, IV). The base-
line characteristics of these 3 SA-NYHA groups are pre-
sented in Table 1. Higher SA-NYHA class was associated
with a larger proportion of patients living alone, greater
number of medications taken daily, significantly higher
number of patients treated with spironolactone, antiarrhyth-
mic drugs, digoxin and higher dose of furosemide, or
needing help with their medications. Patients from higher
SA-NYHA groups also had longer length of stay in hospital
and worse quality of life, measured by total MLHFQ score,
both its physical and emotional dimensions, and by EQ-5D
at baseline.
Table 1. Baseline Comparison of SA-NYHA Groups of all Patients: Demographic and Clinical Variables
Variable
SA-NYHA I/II
(n5 97) Number (%)
or Mean (SD)
SA-NYHA III
(n5 99) Number (%)
or Mean (SD)
SA-NYHA IV
(n5 97) Number (%)
or Mean (SD)
P Value (Chi-squared
Test, Except
where Indicated)
Female sex 27 (27.8%) 42 (42.4%) 38 (39.2%) P 5 .085
Mean (SD) age (y) 78.8 (8.2) 76.8 (9.99) 75.6 (9.2) P 5 .052*
Living alone 31 (32.0%) 47 (47.5%) 32 (33.0%) P 5 .043
Social classy
High (I, II, IIINM)*** 53 (55.8%) 50 (52.1%) 36 (39.6%) P 5 .069
Abbreviated Mental Test 9.32 (0.93) 9.18 (1.34) 9.18 (1.07) P 5 .7208*
No. of prescribed drugs taken daily 7.15 (2.15) 7.52 (2.13) 8.70 (2.78) P ! .001*
Help with medicationz 36 (38.7%) 63 (64.3%) 65 (68.4%) P ! .001
Medication adherence aidx 13 (13.7%) 22 (22.5%) 26 (27.1%) P 5 .070
Medication at discharge includes:
ACE inhibitor/angiotensin-2
receptor antagonist
77 (79.4%) 79 (79.8%) 71 (73.2%) P 5 .466
Loop diuretic 91 (93.8%) 98 (99.0%) 95 (97.9%) P 5 .086
Spironolactone 28 (28.9%) 40 (40.4%) 46 (47.4%) P 5 .028
b-blocker 45 (46.4%) 38 (38.4%) 31 (32.0%) P 5 .118
Antiarrhythmic drug 9 (9.3%) 8 (8.1%) 18 (18.6%) P 5 .048
Warfarin 36 (37.1%) 33 (33.3%) 31 (32.0%) P 5 .735
Antiplatelet drug 53 (54.6%) 51 (51.5%) 50 (51.6%) P 5 .882
Digoxin 22 (22.7%) 40 (40.4%) 34 (35.1%) P 5 .026
Furosemide dose (mg)jj 71.5 (38.0) 84.5 (42.1) 107.9 (72.5) P ! .001*
Systolic BP 140.1 (28.6) 133.5 (27.9) 128.9 (23.7) P 5 .02{
Diastolic BP 79.1 (17.8) 77.0 (15.2) 73.8 (15.0) P 5 .068{
Heart rate 89.4 (27.1) 92.2 (21.8) 91.2 (20.1) P 5 .70{
Sodium 138.9 (3.8) 137.7 (4.1) 137.1 (4.7) P 5 .008*
Creatinine 132.8 (56.8) 141.0 (65.9) 139.0 (63.2) P 5 .70*
Hemoglobin 13.0 (2.2) 12.5 (2.1) 12.3 (2.1) P 5 .04*
Body mass index 25.9 (4.8) 27.2 (5.4) 28.3 (6.1) P 5 .02*
Acute hospital length of stay
at baseline (days)
8.9 (7.1) 12.7 (14.1) 12.9 (10.9) P 5 .004*
CCU/ICU/HDU admissions 13 (13.4%) 3 (3.03%) 8 (8.3%) P 5 .030
MLHFQ total** 31.5 (20.98) 49.1 (21.3) 57.1 (22.9) P ! .0001{
MLHFQ physical dimension 14.9 (10.6) 24.5 (9.3) 28.1 (9.5) P 5 .0001*
MLHFQ emotional dimension 5.6 (5.8) 9.1 (7.4) 10.8 (7.6) P 5 .0001*
EQ-5D 0.72 (0.25) 0.53 (0.32) 0.47 (0.35) P ! .0001{
SA-NYHA, self-assigned New York Heart Association; ACE, angiotensin-converting enzyme; BP, blood pressure; CCU, care unit; ICU, intensive care
unit; HDU, high dependency unit; MLHFQ, Minnesota Living with Heart Failure questionnaire; EQ-5D.
*Kruskal-Wallis test.
ySocial class data recorded for 281 patients.
zData recorded for 285 patients.
xData recorded for 288 patients.
jjCalculated for 248 patients.
{Analysis of variance.
**Calculated for 274 patients.
***UK Registrar General’s classification: I5 professional, II5 semi-professional, IIINM5 skilled non-manual.
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Participants could either complete our SA-NYHA ques-
tionnaire independently or with help from a trial researcher
or a carer. In total, 157 (54%) completed it independently
(SELF subgroup) and 135 (46%) needed help from the
researcher or carer/relative to choose the statement which
best described their functional status (HELP subgroup).
For 1 patient, it was not recorded who completed the ques-
tionnaire. The baseline characteristics of these 2 subgroups
are presented in Table 2. Those in the HELP group
appeared to be of higher SA-NYHA class, though this
was not statistically significant. However, the HELP sub-
group were significantly more likely to be female, older,
living alone, to have worse abbreviated mental test scores,
to use a medication adherence aid, and to need help with
their medication. The HELP group also reported a signifi-
cantly lower (better) quality of life on the MLHFQ, but
no difference was detected on the EQ-5D measure.
Number of Hospital Readmissions
Two patients (0.7%) had incomplete Hospital Episode
Statistics data as they moved outside the study area during
follow-up. A total of 149 of the remaining 291 patients
were readmitted to hospital at least once during the fol-
low-up period with a total of 246 admissions (a mean of
0.85 admissions per patient). The distribution of admissions
among the SA-NYHA groups is presented in Table 3. The
unadjusted rate ratio for increasing SA-NYHA class was
1.21, and adjusted this was 1.26 (95% confidence interval
[CI] 1.06e1.51, P5 .01) when SA-NYHA class was con-
sidered as a continuous variable (I/II to III to IV). Table 3
presents the results with SA-NYHA considered categori-
cally with SA-NYHA I/II compared against Class III and
Class IV. In the final model, the following variables were
also significantly associated with admission: number of
drugs taken daily (increasing drugs associated with in-
creased admission [rate ratio5 1.08]), antiarrhythmic drugs
(use associated with fewer admissions [rate ratio5 0.56]),
dose of furosemide (higher dose reducing admissions
[rate ratio5 0.997]), diastolic blood pressure (higher blood
pressure reducing admissions [rate ratio5 0.991]), and
whether the patient had been admitted to intensive or coro-
nary care units (admission increasing admission [rate
ratio5 1.61]).
Separate analysis of re-admissions among the subgroup
of patients who classified their SA-NYHA status them-
selves (SELF group) also identified that SA-NYHA I/II pa-
tients had the lowest rate of admissions. However, in this
subgroup analysis only the difference between SA-NYHA
III patients and SA-NYHA I/II patients was statistically sig-
nificant after adjustment for baseline characteristics.
Table 2. Baseline Comparison of SELF and HELP Groups of Patients: Demographic and Clinical Variables
Variable
SELF (n5 157)
Number (%) or Mean (SD)
HELP (n5 135)
Number (%) or Mean (SD)
P Value (Chi-squared Test,
except where Indicated*)
SA-NYHA class
I/II 54 (34.4%) {43 (31.9%)} P 5 .510
III 56 (35.7%) {43 (31.9%)}
IV 47 (29.9%) {49 (36.3%)}
Female 44 (28.0%) 63 (46.7%) P 5 .001
Age 75.67 (9.4) 78.64 (8.9) P 5 .0042*
Living alone 51 (32.5%) 59 (43.7%) P 5 .049
Social class - High (I, II, IIINM)y 76 (49.7%) 62 (48.4%) P 5 .837
Abbreviated Mental Test 9.46 (0.76) 8.95 (1.40) P 5 .0011*
No. of prescribed drugs taken daily 7.72 (2.3) 7.87 (2.6) P 5 .8438*
Help with medicationz 74 (49.0%) 90 (67.2%) P 5 .002
Medication adherence aidx 26 (16.8%) 35 (26.3%) P 5 .048
MLHFQjj 52.7 (23.6) 38.1 (22.4) P ! .001*
EQ-5D 0.57 (0.31) 0.57 (0.35) P 5 .60
SA-NYHA, self-assigned New York Heart Association; MLHFQ, Minnesota Living with Heart Failure questionnaire; EQ-5D, quality of life questionnaire.
*Mann-Whitney nonparametric test.
ySocial class data recorded for 281 patients (153 SELF and 128 HELP).
zData recorded for 285 patients (151 SELF and 134 HELP).
xData recorded for 288 patients (153 SELF and 133 HELP).
jjCalculated for 274 patients (147 SELF and 127 HELP).
Table 3. Number of Emergency Readmissions by SA-NYHA Group during 6 Months’ Follow-up
n No. Admissions Mean Rate
Unadjusted Rate Ratio vs
SA-NYHA I/II (95% CI)*
Adjusted Rate Ratio vs.
SA-NYHA 1/II (95% CI)y
SA-NYHA I/II 97 59 0.61 1.0 1.0
SA-NYHA III 98 98 1.0 1.64 (1.19e2.27, P5 .003) 1.56 (1.08e2.24, P5 .02)
SA-NYHA IV 96 89 0.93 1.52 (1.10e2.12, P5 .012) 1.64 (1.13e2.37, P5 .008)
SA-NYHA, self-assigned New York Heart Association.
*Assuming a linear effect, the overall rate ratio across the 3 groups is 1.21 (unadjusted) and 1.26 (adjusted).
yPoisson model after adjustment for differences in baseline characteristics among the SA-NYHA groups
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Quality of Life
SA-NYHA class was a significant predictor of quality of
life of patients at 6 months of follow-up (Table 4) with
higher (worse) SA-NYHA scores predicting worse quality
of life at follow-up as measured by both the MLHFQ and
the EQ-5D. It should be noted that MLHFQ was completed
by 158 patients (66% of the participants who survived 6
months) and compared with patients who did not complete
the MLHFQ at 6 months; those who did were slightly youn-
ger, had higher (better) abbreviated mental test scores, and
were more likely to live alone (data available from the
authors). In contrast, EQ-5D scores were completed by
214 patients at 6 months’ follow-up with 54 additional
patients included who died (given score of 0). Thus, EQ-
5D scores were available on 91% of participants at 6
months (Table 4). Completers of EQ-5D were similar at
baseline to noncompleters.
In both the univariable and the multivariable analysis ad-
justing for baseline differences among the 3 NYHA class
groups, the mean MLHFQ scores at 6 months follow-up
differed significantly among the 3 groups (unadjusted
P ! .0001, adjusted P5 .002). In the final model, other
significant predictors of 6-month MLHFQ score were 3-
month MLHFQ scores, use of an antiarrhythmic (associated
with better quality of life), and body mass index (higher
body mass index was associated with worse quality of
life). In the adjusted analysis, SA-NYHA Class I/II had
MLHFQ scores a mean of 17.1 points lower (better) than
SA-NYHA Class IV, and SA-NYHA Class III patients’
scores were on average 7.3 points lower (better) than SA-
NYHA Class IV. The adjusted R-squared for the final
model was 0.75, whereas the model solely containing
SA-NYHA class had an adjusted R-squared of 0.23; imply-
ing almost a quarter of the variance of the final MLHFQ
results was explained by baseline SA-NYHA class. Similar
results were found when the analysis was limited to those
patients who self-classified their SA-NYHA class, though
in this case our final model explained almost 90% of the
variance, and both SA-NYHA III and SA-NYHA IV dif-
fered significantly from SA-NYHA I/II. It should be noted
that due to missing values, both the adjusted models were
calculated on approximately 30% of the participants. Fi-
nally, baseline SA-NYHA class was also found to predict
both physical and emotional dimension scores of the
MLHFQ at 6 months.
In both the univariable analysis and multivariable analy-
sis of EQ-5D, results were significantly different among the
3 groups with mean scores of EQ-5D at 6 months higher
(better) in those with lower SA-NYHA classes (unadjusted
P ! .0001, adjusted P5 .047). When results were limited
to self-completers, SA-NYHA class was no longer signifi-
cantly associated with final EQ-5D score (adjusted
P5 .11).
Mortality
Mortality data were available for all 293 patients. A total of
91 deaths (31.1%) from all causes occurred during follow-up.
Lower self-assigned NYHA class was associated with lower
mortality rate: 19.6% among SA-NYHA I/II group, 34.3%
among SA-NYHA III, and 39.2% among SA-NYHA IV. Sur-
vival plots for the 3 groups showed similar survival between
those classified as SA-NYHA III and IVand analysis demon-
strated no statistically difference between these 2 groups, so
these groups were merged. Survival analysis did demonstrate
marked difference in survival between SA-NYHA I/II
patients and those classified as III/IV (unadjusted hazard
ratio5 2.15; 95% confidence interval 1.29 to 3.56,
P5 .002) (Fig. 1). Similar results were obtained after adjust-
ing for baseline differences (hazard ratio5 2.03, 95%
CI 1.22e3.39, P5 .007) and when limited to those self-
classifying their SA-NYHA class with unadjusted hazard
ratio5 2.36 (adjusted hazard ratio5 2.69, 95% CI
1.33e5.45, P5 .006). Inspection of Schoenfeld residual
and ‘‘log-log’’ plots and a chi-squared test using the Schoen-
feld residuals, suggested that the proportional hazards
assumption was not violated.
Discussion
Clinician-assigned NYHA class is an established predictor
of outcomes in heart failure.4,17,18 Our study has demon-
strated that heart failure patients’ own assessment of their
Table 4. Mean MLHFQ Scores and EQ-5D Scores for SA-NYHA Groups (ALL Patients and SELF-assessed Patients) at Baseline
and at 6 Months’ Follow-up
SA-NYHA I/II SA-NYHA III SA-NYHA IV
Mean
Score (SD)
No. of
Respondents
Mean
Score (SD)
No. of
Respondents
Mean
Score (SD)
No. of
Respondents P Value
ALL patients
MLHFQ at 6 months* 29.1 (19.5) 56 50.9 (28.4) 51 60.0 (23.0) 51 P 5 .002y
EQ-5D at 6 monthsz 0.60 (0.32) 91 0.38 (0.36) 90 0.34 (0.35) 87 P 5 .047y
SELF patients
MLHFQ at 6 months* 28.9 (20.7) 32 49.8 (28.4) 32 62.2 (22.5) 25 P ! .0001y
EQ-5D at 6 monthsz 0.61 (0.33) 51 0.37 (0.35) 50 0.35 (0.35) 42 P 5 .11y
MLHFQ, Minnesota Living with Heart Failure Questionnaire; EQ-5D; SA-NYHA: self-assigned New York Heart Association.
*Low scores imply better health.
yAnalysis of variance adjusted for baseline differences.
zHigh scores imply better health.
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NYHA class is also predictive of future outcomes. Higher
(worse) self-assigned NYHA class was associated with in-
creased hospitalization rates, worse quality of life, and de-
creased survival. Interestingly, the SA-NYHA classification
in this study also predicted not only the physical dimension
of the MLHFQ measure, but also the emotional dimension.
Usually the NYHA class is assigned by physicians or nurses
based on their subjective interpretation of patients’ cardiac
symptoms, their interpretation of impact on daily activities,
and the results of objective clinical investigations.1,2 There is
no agreed-on method of assigning NYHA class. A limitation
of the NYHA classification is its poor interobserver and intra-
observer reproducibility. In a recent study, providers used
a considerable variety of different questions and criteria to de-
termine the NYHA classification.19 Furthermore, the interob-
server concordance was little better than chance: for a series of
50 patients, 2 independent cardiologists assessors agreed on
the NYHA class in only 54% of cases.19
It has been suggested that a way to improve its reliability
may be to use the criteria as a patient self-report instru-
ment.1 The NYHA classification is based on the main
symptoms of heart failure (breathlessness, fatigue, and pal-
pitations) as experienced by patients and the limitation in
their physical activity resulting from their condition.3 Being
subjective experiences, symptoms should in principle be
most reliably elicited by asking patients directly. It has
been argued that functional status may be appropriate for
self-report because it is affected by a variety of psycholog-
ical, social, and environmental influences experienced by
the patient.1 Our study provides evidence that self-reported
functional status has predictive validity.
An advantage of our study is that it explicitly describes
the method used for assigning the SA-NYHA class. In con-
trast, a recent review showed that 99% of the reviewed
papers did not reference the methods they used to distin-
guish between different classes of patients.19 An additional
strength of our study is that the questionnaire is very brief
and was derived directly from the NYHA criteria.
Our study was limited by there being no clinician assess-
ment to compare with patients’ own assessment. Further-
more, follow-up was reasonably brief (limited to 6 months)
and only 54% of the patients could complete our SA-
NYHA questionnaire themselves. Patients who needed help
selecting their SA-NYHA class were more likely to be older,
had worse abbreviated mental test scores, and needed help
with their medication, indicating that further refinement of
the questions is needed to make them clearer and easier to
use by older or sicker patients. Equally on a positive side, re-
searchers were generic health researchers or research nurses,
none of whom had a background in cardiology implying that
no specialist expertise was used to assign SA-NYHA class
where help was given. A further weakness of our study was
that in general we only identified differences between mild
(SA-NYHA I/II) heart failure and moderate/severe (SA-
NYHA III/IV) heart failure. We found little difference
between SA-NYHA Class III and IV except for 1 quality of
life measure. This finding is in line with previous research,
which has often failed to find prognostic differences between
NYHA Classes II and III or between NYHA Classes III and
IV.20 Finally, our study measure was not validated against
objective measures of functional capacity.
We are not aware of other published studies in which
NYHA was assigned by directly asking patients to choose
the NYHA class that best describes their condition. Our study
supports earlier findings that patients’ self-reported symptoms
have predictive significance for outcomes in heart failure.
NYHA functional class is a well known and simple risk strat-
ification tool. We have demonstrated that it has a clinically
significant predictive value when used directly by patients.
Further research is necessary to refine the instrument for
self-determining NYHA class and to validate it against objec-
tive measures of functional capacity in heart failure and clini-
cian assessment. In conclusion, this study suggests that self-
assigned NYHA class appears to predict patient outcome. It
could be used by researchers who need a quick tool to stratify
patients with heart failure, or by nonspecialist clinical staff
needing a simple estimate of disease severity.
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